Preventing bone marrow suppression from chemo in advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with advanced non-small cell lung cancer (stage IIIB, IIIC, or IV) that cannot be removed with surgery.
- You have at least one tumor that can be measured on scans.
- You are about to start first- or second-line chemotherapy (such as platinum plus pemetrexed, docetaxel, or paclitaxel).
- Your general health is good (ECOG score 0 or 1, meaning you can care for yourself and are up and about more than half the day).
- You have no other active cancer within the last 5 years (except treated skin cancers or early-stage cervical cancer).
- You have no serious heart problems (like uncontrolled heart disease, recent stroke, or heart failure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug that may help protect your bone marrow during chemotherapy, possibly reducing side effects like low blood counts. It is for people with certain advanced or recurrent solid tumors who are about to start a specific chemo regimen.
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
This trial tests a drug called trilaciclib, given before chemotherapy, to see if it can protect your bone marrow and help prevent dangerous drops in blood cell counts. If you have head and neck cancer that has returned or spread and haven't had prior drug treatment, this might help you stay stronger during chemo.
This trial tests a drug called trilaciclib that may protect your bone marrow during chemotherapy for advanced bile duct or pancreatic cancer, potentially reducing side effects like low blood counts. It aims to make chemotherapy safer and more tolerable.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests whether taking trilaciclib alongside standard chemotherapy can help prevent low blood cell counts (myelosuppression) in people with limited-stage small cell lung cancer. It may help you stay stronger during treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.